Brain tumors are classified by type and grade using the WHO CNS5 system, which now includes molecular markers like IDH mutation and 1p/19q codeletion. Treatment has shifted from one-size-fits-all to personalized approaches, with new drugs like vorasidenib improving outcomes for low-grade gliomas.